Do I need a PR strategy?

January 23, 2019 root 0

When you start a business, especially one rooted in the exciting and fast-moving world of biotechnology, it can be easy to find yourself overwhelmed by all the different responsibilities. You’ve established a set of key strategies and visions, written your five-year development plan, even designed a logo and begun to think about defining your brand when suddenly it hits you – how do we get the word out there? What about our public image? Read more…

Attached Issue № 0219

Could you write for Biostart?

January 2, 2019 root 0

Over the past decade of running conferences in biotechnology, we’ve seen first-hand the impact start-up companies have in the industry. We’ve noticed over the past few years that there’s a real gap in the market for good, quality advice for those moving from academia to industry, and so we are excited to be launching Biostart: the free, online magazine for CXOs looking to develop their biotech business.

Biting the data bullet at GlaxoSmithKline

May 15, 2019 Jane 0

GSK’s size undoubtedly makes it a big ship to turn when integrating new tools like machine learning. What this case study shows is that the focus of any organisation today – both large and small, must be on positioning their infrastructure and their personnel in such a way that new trends can be utilised quickly to retain competitive advantage.

Here the author of The AI Advantage, Thomas H. Davenport, examines how GlaxoSmithKline R&D successfully transformed their data allowing them to utilise AI and lay the foundation for creating better drugs, quicker.

Many large organizations eventually realize that they don’t have the data environments they need to succeed with broad-scale AI to work. For GlaxoSmithKline’s (GSK) Research and Development (R&D) organization, that time was in early 2015. The president (at that time) of the unit Patrick Vallance and his senior colleagues deliberated on whether their data environment was of sufficient quality and integration to use tools like machine learning to help develop new drugs…

Attached Issue № 0219
Company spotlight_Biostart Magazine

In my experience: Alex Goddard, AOBiome

May 1, 2019 Jane 0

A scientist by training, Alex Goddard has worked in large companies – namely Novartis’ neuroscience drug discovery division and in small companies including Tal Medical and AOBiome, where he currently serves as VP of Research & Development. He spoke to us about the main differences between the two.

My entry into industry at a big pharma was very edifying. My time at Novartis taught me how the industry prioritizes certain questions in science and showed me the key questions to ask. Novartis was good at providing opportunities to learn and they offered short courses on various aspects of drug discovery and drug development. One of the interesting structural aspects of big pharma is that…

Attached Issue № 0219

Collaboration, Translation And The Future Of Microbiome Innovation

April 17, 2019 root 0

Translation. When we hear this word, it may evoke feelings of excitement, adventure and possibility that come with learning different languages or travelling to a foreign country. For scientists, ‘translation’ also suggests moving research findings from the laboratory into clinical practice. Just as words are translated, so too are research findings.

Read more…

Attached Issue № 0219
Inside the mind of investors

Spotlight on: Seventure

April 10, 2019 Jane 0

Founded in 1997, Seventure is a European leader in venture capital, with €691 under management at the end of 2017. Operating primarily in Digital Technologies and Life Sciences, they’ve focused particularly on investing in microbiome, creating the first microbiome fund Health for Life. Since 2015, it has…

Attached Issue № 0219
Biostart-Magazine-Sitting-Down-With

David Kyle, Evolve Biosystems

March 27, 2019 Jane 0

Dr. David Kyle has co-founded biotech companies for 35 years in nutrition and health including Martek Biosciences which was acquired in 2011 for $1.1 billion. For the first issue of Biostart, he spoke to us about the lessons he’s learned during his career.

Where did Evolve begin?

Evolve’s work is based on 15 years of previous research at the University of California at Davis. A cross-functional team of world-class scientists made an incredible discovery. The early microbiome of the infant is defined by the 15% of energy in human breast milk that is not directly available to the infant, but rather it is tied up in a soluble fibre (Human Milk Oligosaccharides or HMO) that feeds the new-born infant gut microbiome.

Interestingly, only a single bacterial species, Bifidobacterial infantis, has the capability for completely consuming all those HMO and remarkably, this species has been lost from most infants in the developed world due primarily to a lifetime exposure to antibiotics. The seeding of an infant’s gut microbiome has historically come from its mother’s gut microbiome, but mothers in the U.S. today have had 15-20 courses of antibiotics from the time they were born until the time they deliver their first baby. Her microbiome diversity has been depleted significantly, including this important symbiont and if mom does not have the B. infantis, she cannot pass it on to her baby and the symbiosis has…

Attached Issue № 0219

Investing in the future

March 13, 2019 Jane 0

Charlie Curtis teaches businesses how to innovate, focusing on the positive impact they can have for future generations. But keen to have a positive impact himself, Charlie, alongside his business partner Tim Kruger, starts revolutionary new ventures to address environmental issues.

Everyone should have a wilderness experience where they walk across a desert or climb a mountain or cycle across a country. In 2008, I spent three months in a small boat with three others, sailing from Argentina to Cape Town via the Antarctic. The camaraderie with a team that size is…

Load More